Source study found

Story checked

DNA sequencing test finds answers for patients with inherited muscle disease (opens in a new tab)

medicalxpress.com · 2026-09-25

Short answerEvidenceSource

Short answer

Not supported

Not supported.

One claim goes further than the study. 3 other points were not covered by the paper.

1 overstated
3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

DNA sequencing test finds answers for patients with inherited muscle disease

medicalxpress.com · 2026-09-25

The story’s checkable claims.

Read the original story

NewsLink checks it

Not supported

One claim overstates the study. Three claims the study doesn't address.

1 overstated
3 not covered

Open claim evidence

The source study

Targeted long-read sequencing enables comprehensive analysis of the genetic and epigenetic landscape of inherited myopathies

Nature Communications · 2026Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedResearchers at the Garvan Institute of Medical Research developed a first-of-its-kind DNA sequencing test for inherited muscle disease that identified genetic causes in people who had remained undiagnosed after years of standard testing.View evidenceHide evidence

As statedfirst test of its kind; years, sometimes decades, without answers

Why this verdict

The abstract-level paper profile supports that the authors developed a targeted long-read sequencing assay/framework for inherited myopathies and that it produced new diagnoses in some patients previously undiagnosed after standard clinical genetic testing. However, the story’s headline-level framing adds claims not supported at abstract depth: that it is the “first test of its kind in the world” and that patients had gone “years, sometimes decades” without answers. The headline therefore outruns the paper evidence available here.

Study evidence

A targeted long-read sequencing assay plus bioinformatics framework was developed to capture genes, diverse variant classes (small variants, structural variants, repeat expansions) and epigenetic signatures implicated in inherited myopathies.

“we developed a targeted long-read sequencing assay and bioinformatics analysis framework that captures the full suite of genes, variants and epigenetic signatures currently implicated in inherited myopathies.”

Study evidence

Targeted long-read sequencing identified new genetic diagnoses in previously undiagnosed inherited myopathy patients.35.5% (11/31)

“Our assay led to new genetic diagnoses in 35.5% (11/31) of patients who remained undiagnosed after standard clinical genetic testing.”

Claim 2 of 4Not coveredPublished in Nature Communications, the study applied the test to 53 Australians with known or suspected inherited muscle disease, including 31 whose previous genetic testing had not found a cause, and more than a third of those unsolved cases received a diagnosis through the new test.View evidenceHide evidence

As stated53 participants; 31 previously unsolved; more than a third diagnosed

Why this verdict

The abstract-level profile supports the key diagnostic-yield result: 35.5% or 11/31 of previously undiagnosed patients received new genetic diagnoses after standard testing had failed. But the abstract profile does not verify several presentation details, including that the full study cohort was 53 people, that they were Australians, or the exact known/suspected cohort composition. Those details may be in the full paper, but they are not verifiable from the supplied abstract-depth profile.

Study evidence

The targeted long-read sequencing assay demonstrated analytical validity and, according to the authors, improved accuracy and resolution compared to existing methods when applied to a cohort of myopathy patients.

“Applying this to a cohort of myopathy patients, we demonstrate the analytical validity of our approach and its improved accuracy and resolution compared to existing methods.”

Study evidence

Targeted long-read sequencing identified new genetic diagnoses in previously undiagnosed inherited myopathy patients.35.5% (11/31)

“Our assay led to new genetic diagnoses in 35.5% (11/31) of patients who remained undiagnosed after standard clinical genetic testing.”

Claim 3 of 4Not coveredThe article says the test uses long-read nanopore sequencing to screen more than 300 genes and can detect multiple types of DNA change, including variants that older methods miss, in a single experiment.View evidenceHide evidence

As statedmore than 300 genes

Why this verdict

The paper profile supports the general claim that the assay is long-read sequencing-based, intended as a single streamlined assay, and captures diverse variant classes plus epigenetic signatures relevant to inherited myopathies, with claimed improved accuracy/resolution versus existing methods. However, the abstract-depth profile does not verify that the platform is specifically nanopore sequencing or that the assay screens more than 300 genes. It also lacks detailed per-class performance metrics, so the broad 'can detect' framing is only partly supported at this depth.

Study evidence

“we developed a targeted long-read sequencing assay and bioinformatics analysis framework that captures the full suite of genes, variants and epigenetic signatures currently implicated in inherited myopathies.”

Study evidence

“Applying this to a cohort of myopathy patients, we demonstrate the analytical validity of our approach and its improved accuracy and resolution compared to existing methods.”

Claim 4 of 4Not coveredThe story says a confirmed diagnosis can change counseling, open access to disability supports and clinical trials, and prompt monitoring for complications such as heart problems; the team is working to bring the test into routine care and estimates it could be available across Australia within about two years.View evidenceHide evidence

As statedwithin about two years

Why this verdict

The abstract-level profile supports clinical diagnostic utility only in the narrow sense that the assay produced new genetic diagnoses in 11/31 previously undiagnosed patients. It does not provide evidence for the story’s downstream claims about counseling, disability supports, clinical-trial access, monitoring for heart complications, or an estimated two-year timeline for Australia-wide availability. These may come from interviews or full-text discussion, but they are not verifiable from the supplied paper profile.

Study evidence

Targeted long-read sequencing identified new genetic diagnoses in previously undiagnosed inherited myopathy patients.35.5% (11/31)

“Our assay led to new genetic diagnoses in 35.5% (11/31) of patients who remained undiagnosed after standard clinical genetic testing.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

The assay is described as capturing diverse variant classes, including small variants, structural variants, repeat expansions, and epigenetic signatures such as D4Z4 hypomethylation.
The story captures the broad idea of multiple DNA-change types, but it does not reflect the paper profile’s explicit epigenetic-signature component. Framing the method only as detecting DNA changes omits a material part of the assay’s claimed scope.
From Targeted long-read sequencing assay and companion bioinformatics pipeline; method comparison/benchmarking
The paper reports analytical validity and claimed improved accuracy/resolution versus existing methods, but the abstract does not provide numerical performance metrics, comparator details, or limits of detection.
The story emphasizes that the test detects variants older methods miss, but it does not convey the abstract-depth limitations: the profile lacks quantitative sensitivity/specificity, concordance, comparator-method detail, or per-variant-class performance metrics.
From method comparison/benchmarking
The diagnostic-yield result is based on a small previously undiagnosed subgroup, and the abstract does not specify cohort selection, representativeness, diagnostic adjudication, independent confirmation, or statistical uncertainty.
The story mentions the previously unsolved subgroup but does not reflect the paper profile’s interpretation-changing limitations around small sample size, selection criteria, confirmation/adjudication, and uncertainty.
From observational cohort diagnostic study

3 things the story did carry across

The paper’s central contribution is development of a targeted long-read sequencing assay plus companion bioinformatics framework for comprehensive inherited-myopathy genetic and epigenetic characterization.
The paper reports new genetic diagnoses in 35.5% (11/31) of patients who remained undiagnosed after standard clinical genetic testing.
The paper profile presents the work as research demonstrating a method and diagnostic utility, not as a test already implemented in routine care.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

in silico

1Lead resultin silicoDevelop a targeted long-read sequencing assay plus bioinformatics framework that can capture diverse genetic variant classes and epigenetic signatures relevant to inherited myopathies (including challenging loci such as D4Z4 with contraction and hypomethylation).Targeted long-read sequencing assay and companion bioinformatics pipelineExpand

In plain English

The paper reports development of a targeted long-read sequencing assay plus a companion bioinformatics analysis framework intended to capture the full suite of genes, diverse variant classes (small variants, structural variants, repeat expansions and complex events) and epigenetic signatures (e.g., D4Z4 contraction and hypomethylation) relevant to inherited myopathies. The authors applied the assay to a patient cohort to demonstrate analytical validity and claimed improved accuracy and resolution versus existing methods, and reported new genetic diagnoses in 35.5% (11/31) of patients who remained undiagnosed after standard clinical genetic testing.

Key findings

A targeted long-read sequencing assay plus bioinformatics framework was developed to capture genes, diverse variant classes (small variants, structural variants, repeat expansions) and epigenetic signatures implicated in inherited myopathies.
The authors claim improved accuracy and resolution compared to existing methods and report demonstrating analytical validity of their approach.

“we developed a targeted long-read sequencing assay and bioinformatics analysis framework that captures the full suite of genes, variants and epigenetic signatures currently implicated in inherited myopathies.”

What this piece can’t prove

3 further details could not be confirmed from the summary.

2secondary dataDemonstrate analytical validity and improved accuracy/resolution versus existing/standard methods when applied to patient samples.method comparison/benchmarkingExpand

In plain English

Analytical validation of a targeted long-read sequencing assay and bioinformatics framework applied to a cohort of inherited myopathy patients, reporting analytical validity and improved accuracy/resolution versus existing methods and yielding new genetic diagnoses in 35.5% (11/31) of patients who remained undiagnosed after standard clinical genetic testing.

Key findings

The targeted long-read sequencing assay demonstrated analytical validity and, according to the authors, improved accuracy and resolution compared to existing methods when applied to a cohort of myopathy patients.
The assay led to new genetic diagnoses in 35.5% (11/31) of patients who remained undiagnosed after standard clinical genetic testing.35.5% (11/31)

“Applying this to a cohort of myopathy patients, we demonstrate the analytical validity of our approach and its improved accuracy and resolution compared to existing methods.”

What this piece can’t prove

Abstract provides limited methodological detail: lacks specific numerical performance metrics (sensitivity, specificity, precision, concordance) for the assay versus comparators.

3 further details could not be confirmed from the summary.

3human in vivoShow clinical/diagnostic utility in a myopathy patient cohort, including additional diagnoses among previously undiagnosed patients after standard clinical genetic testing.observational cohort diagnostic studyExpand

In plain English

In a cohort of patients with inherited myopathies who remained undiagnosed after standard clinical genetic testing, a targeted long-read sequencing assay plus associated bioinformatics and clinical variant interpretation yielded new genetic diagnoses in 11 of 31 patients (35.5%), as reported in the paper abstract.

Key findings

Targeted long-read sequencing identified new genetic diagnoses in previously undiagnosed inherited myopathy patients.35.5% (11/31)

“Our assay led to new genetic diagnoses in 35.5% (11/31) of patients who remained undiagnosed after standard clinical genetic testing.”

What this piece can’t prove

The reported diagnostic-yield numerator/denominator (11/31) implies a small subgroup sample size for this outcome; the abstract does not provide further context on representativeness or follow-up.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer